
European Commission Approves First-Line Tislelizumab Plus Chemo for Metastatic Nasopharyngeal Carcinoma
The European Commission has approved tislelizumab (Tevimbra) plus gemcitabine/cisplatin for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC) that is not amenable to curative surgery or radiotherapy. …